Related Experiment Videos
Heart failure: to digitalise or not? The view against
1Coronary Care Unit, Green Lane Hospital, Auckland, New Zealand.
Insights
Digoxin effectively controls ventricular rate in atrial fibrillation but its role in heart failure is unclear. More research is needed to confirm benefits and assess mortality risks before widespread use.
Area of Science:
- Cardiology
- Clinical Pharmacology
Background:
- The clinical utility of digoxin remains debated despite its long-standing use.
- Digoxin is established for ventricular rate control in atrial fibrillation, but its efficacy in heart failure with sinus rhythm is less defined.
Purpose of the Study:
- To evaluate the current evidence on digoxin's role in heart failure and atrial fibrillation.
- To assess the safety profile and therapeutic limitations of digoxin, including its narrow therapeutic index and potential adverse effects.
Main Methods:
- Review of existing clinical trials and pooled analyses concerning digoxin's efficacy and safety.
- Analysis of digoxin's pharmacokinetic interactions and its impact on myocardial demands and arrhythmias.
Main Results:
- Limited high-quality trial data exists, with available studies often small and showing variable patient benefits.
- Digoxin has a narrow therapeutic:toxic ratio, is affected by drug interactions, and can increase peripheral resistance and myocardial workload.
- Evidence for digoxin improving symptoms or exercise capacity is inconclusive, and no trials have adequately assessed its impact on mortality.
Conclusions:
- Angiotensin-converting enzyme (ACE) inhibitors are recommended as first-line therapy due to their safety and proven benefits in heart failure.
- Caution is advised with digoxin use until large-scale mortality trials establish its safety and efficacy.
- Digoxin should be considered a third-line therapy for heart failure pending further evidence.
Abstract:
Despite extensive clinical experience the role of digoxin is still not well defined. In patients with atrial fibrillation digoxin is beneficial for ventricular rate control. For patients in sinus rhythm and heart failure the situation is less clear. Digoxin has a narrow therapeutic:toxic ratio and concentrations are affected by a number of drugs. Also, digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing arrhythmias. There is a paucity of data from well-designed trials. The trials that are available are generally small with limitations in design and these show variation in patient benefit. More convincing evidence is required showing that digoxin improves symptoms or exercise capacity. Furthermore, no trial has had sufficient power to evaluate mortality. Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction (MI). Angiotensin-converting enzyme (ACE) inhibitors should be used first as they are safer, do not require blood level monitoring, modify progression of disease, relieve symptoms, improve exercise tolerance and reduce mortality. Caution should be exercised in using digoxin until large mortality trials are completed showing either benefit or harm. Until then digoxin should be considered a third-line therapy.